Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S372-S378

  Reynard, Olivier ^a   Volchkov, Viktor E ^a  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

Author keywords

Ebola virus; filovirus; glycoprotein GP; virus neutralizing antibody

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3327; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; PROTEIN BINDING; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; EBOLAVIRUS; ENDOSOME; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; VIRION; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; EBOLA HEMORRHAGIC FEVER; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; VERO CELL LINE; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; EBOLAVIRUS; GLYCOPROTEINS; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; PROTEIN BINDING; VERO CELLS; VIRION; VIRUS INTERNALIZATION;

EID: 84943244784     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv303     Document Type: Article

References (39)

1. Siegert R, Shu HL, Slenczka W. Isolation and identification of the "Marburg virus." Ger Med Mon 1968; 13:514-8.
2. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271-93.
3. Bowen ET, Platt GS, Simpson DI, McArdell LB, Raymond RT. Ebola haemorrhagic fever: experimental infection of monkeys. Trans R Soc Trop Med Hyg 1978; 72:188-91.
4. Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010; 155:2083-103.
5. Feldmann H, Klenk HD, Sanchez A. Molecular biology and evolution of filoviruses. Arch Virol Suppl 1993; 7:81-100.
6. Volchkova VA, Vorac J, Repiquet-Paire L, Lawrence P, Volchkov VE. Ebola virus GP gene polyadenylation versus RNA editing. J Infect Dis 2015; 212(suppl 2):S191-8.
7. Volchkov VE, Volchkova VA, Chepurnov AA, et al. Characterization of the L gene and 5' trailer region of Ebola virus. J Gen Virol 1999; 80(Pt 2):355-62.
8. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallelorientated homodimer. Virology 1998; 250:408-14.
9. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291:1965-9.
10. Negredo A, Palacios G, Vazquez-Moron S, et al. Discovery of an ebolavirus-like filovirus in europe. PLOS Pathog 2011; 7:e1002304.
11. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 1996; 93:3602-7.
12. Feldmann H, Muhlberger E, Randolf A, et al. Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. Virus Res 1992; 24:1-19.
13. Agopian A, Castano S. Structure and orientation study of Ebola fusion peptide inserted in lipid membrane models. Biochim Biophys Acta 2014; 1838:117-26.
14. Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 2001; 75:1576-80.
15. Elliott LH, Kiley MP, McCormick JB. Descriptive analysis of Ebola virus proteins. Virology 1985; 147:169-76.
16. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000; 74:4933-7.
17. Yang Z, Delgado R, Xu L, et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998; 279: 1034-7.
18. Hashiguchi T, Fusco ML, Bornholdt ZA, et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 2015; 160:904-12.
19. Mulherkar N, Raaben M, de la Torre JC, Whelan SP, Chandran K. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology 2011; 419:72-83.
20. Kaletsky RL, Simmons G, Bates P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 2007; 81: 13378-84.
21. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308:1643-5.
22. Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477:340-3.
23. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454:177-82.
24. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010; 401:228-35.
25. Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013; 3:3365.
26. OswaldWB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection inmonkeys. PLOS Pathog 2007; 3:e9.
27. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 2001; 75:4649-54.
28. Reynard O, Volchkov V, Peyrefitte C. [A first outbreak of Ebola virus in West Africa]. Med Sci (Paris) 2014; 30:671-3.
29. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, Volchkov VE. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 2009; 83:9596-601.
30. Garbutt M, Liebscher R,Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65.
31. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91:9564-8.
32. Wulff NH, Tzatzaris M, Young PJ. Monte Carlo simulation of the Spearman-Kaerber TCID50. J Clin Bioinformatics 2012; 2:5.
33. Schudt G, Kolesnikova L, Dolnik O, Sodeik B, Becker S. Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances. Proc Natl Acad Sci USA 2013; 110:14402-7.
34. Miller EH, Obernosterer G, Raaben M, et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J 2012; 31:1947-60.
35. Alazard-Dany N, Volchkova V, Reynard O, et al. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 2006; 87:1247-57.
36. Kuhn JH, Radoshitzky SR, Guth AC, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006; 281:15951-8.
37. Murin CD, Fusco ML, Bornholdt ZA, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA 2014; 111:17182-7.
38. Maruyama T, Parren PW, Sanchez A, et al. Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 1999; 179(suppl 1):S235-9.
39. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 2006; 80:4174-8.